157 related articles for article (PubMed ID: 7204094)
1. The effects of oxygen affinity and gelation of hemoglobin S crosslinked by reaction with methyl acetimidate.
Chao TL; Berenfeld MR; Gelbart T; Gabuzda TG
Hemoglobin; 1981; 5(1):47-72. PubMed ID: 7204094
[TBL] [Abstract][Full Text] [Related]
2. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
[TBL] [Abstract][Full Text] [Related]
3. Modification of sickle hemoglobin by acetaldehyde and its effect on oxygenation, gelation and sickling.
Abraham EC; Stallings M; Abraham A; Garbutt GJ
Biochim Biophys Acta; 1982 Jul; 705(1):76-81. PubMed ID: 7115734
[TBL] [Abstract][Full Text] [Related]
4. Determinants of red cell sickling. Effects of varying pH and of increasing intracellular hemoglobin concentration by osmotic shrinkage.
Bookchin RM; Balazs T; Landau LC
J Lab Clin Med; 1976 Apr; 87(4):597-616. PubMed ID: 5563
[TBL] [Abstract][Full Text] [Related]
5. Chemical modifications that inhibit gelation of sickle hemoglobin.
Benesch R; Benesch RE; Yung S
Proc Natl Acad Sci U S A; 1974 Apr; 71(4):1504-5. PubMed ID: 4524653
[TBL] [Abstract][Full Text] [Related]
6. Current status of methyl acetimidate as an extracorporeal antisickling agent.
Chao TL; Berenfeld MR; Gabuzda TG
Am J Pediatr Hematol Oncol; 1984; 6(1):55-8. PubMed ID: 6711765
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
[TBL] [Abstract][Full Text] [Related]
8. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
[TBL] [Abstract][Full Text] [Related]
9. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
[TBL] [Abstract][Full Text] [Related]
10. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
Iyamu EW; Turner EA; Asakura T
Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171
[TBL] [Abstract][Full Text] [Related]
11. Pyridoxal phosphate as an antisickling agent in vitro.
Kark JA; Tarassoff PG; Bongiovanni R
J Clin Invest; 1983 May; 71(5):1224-9. PubMed ID: 6853710
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl adipimidate: a new antisickling agent.
Lubin BH; Pena V; Mentzer WC; Bymun E; Bradley TB; Packer L
Proc Natl Acad Sci U S A; 1975 Jan; 72(1):43-6. PubMed ID: 1054514
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of inhibition of sickling by dimethyl adipimidate. Effects of intertetramer cross-linking.
Pennathur-Das R; Heath R; Mentzer W; Lubin B
Biochim Biophys Acta; 1984 Dec; 791(2):259-64. PubMed ID: 6509069
[TBL] [Abstract][Full Text] [Related]
14. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
15. Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes.
Monplaisir N; Merault G; Poyart C; Rhoda MD; Craescu C; Vidaud M; Galacteros F; Blouquit Y; Rosa J
Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9363-7. PubMed ID: 3467311
[TBL] [Abstract][Full Text] [Related]
16. Responses of normal and sickle cell hemoglobin to S-nitroscysteine: implications for therapeutic applications of NO in treatment of sickle cell disease.
Bonaventura C; Godette G; Ferruzzi G; Tesh S; Stevens RD; Henkens R
Biophys Chem; 2002 Jul; 98(1-2):165-81. PubMed ID: 12128197
[TBL] [Abstract][Full Text] [Related]
17. Aggregation of hemoglobin S modified by bifunctional imidoesters.
Adachi K; Kikugawa K; Asakura T
Biochim Biophys Acta; 1983 Feb; 742(3):597-606. PubMed ID: 6838892
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of erythrocyte sickling in vitro by DL-glyceraldehyde.
Nigen AM; Manning JM
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):367-71. PubMed ID: 264689
[TBL] [Abstract][Full Text] [Related]
19. Erythrocyte Hb-S concentration. An important factor in the low oxygen affinity of blood in sickle cell anemia.
Seakins M; Gibbs WN; Milner PF; Bertles JF
J Clin Invest; 1973 Feb; 52(2):422-32. PubMed ID: 4683881
[TBL] [Abstract][Full Text] [Related]
20. Increasing haemoglobin oxygen affinity to prevent sickling: abnormal haemoglobin variants as models.
Franklin IM; Huehns ER; Rosemeyer MA
Br J Haematol; 1986 Oct; 64(2):319-29. PubMed ID: 3778826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
